全文获取类型
收费全文 | 93915篇 |
免费 | 9319篇 |
国内免费 | 4731篇 |
专业分类
耳鼻咽喉 | 2596篇 |
儿科学 | 386篇 |
妇产科学 | 1707篇 |
基础医学 | 10666篇 |
口腔科学 | 3400篇 |
临床医学 | 6730篇 |
内科学 | 11636篇 |
皮肤病学 | 1976篇 |
神经病学 | 218篇 |
特种医学 | 4292篇 |
外国民族医学 | 122篇 |
外科学 | 13764篇 |
综合类 | 16547篇 |
现状与发展 | 23篇 |
预防医学 | 2028篇 |
眼科学 | 396篇 |
药学 | 4625篇 |
14篇 | |
中国医学 | 1136篇 |
肿瘤学 | 25703篇 |
出版年
2024年 | 116篇 |
2023年 | 1277篇 |
2022年 | 2067篇 |
2021年 | 3642篇 |
2020年 | 3152篇 |
2019年 | 2997篇 |
2018年 | 2865篇 |
2017年 | 3275篇 |
2016年 | 3701篇 |
2015年 | 4227篇 |
2014年 | 6217篇 |
2013年 | 5459篇 |
2012年 | 5652篇 |
2011年 | 6124篇 |
2010年 | 4988篇 |
2009年 | 4925篇 |
2008年 | 5119篇 |
2007年 | 5427篇 |
2006年 | 5071篇 |
2005年 | 4529篇 |
2004年 | 3577篇 |
2003年 | 3139篇 |
2002年 | 2680篇 |
2001年 | 2580篇 |
2000年 | 2187篇 |
1999年 | 1754篇 |
1998年 | 1596篇 |
1997年 | 1430篇 |
1996年 | 1258篇 |
1995年 | 1068篇 |
1994年 | 978篇 |
1993年 | 679篇 |
1992年 | 594篇 |
1991年 | 517篇 |
1990年 | 437篇 |
1989年 | 380篇 |
1988年 | 363篇 |
1987年 | 291篇 |
1986年 | 240篇 |
1985年 | 260篇 |
1984年 | 212篇 |
1983年 | 151篇 |
1982年 | 172篇 |
1981年 | 147篇 |
1980年 | 136篇 |
1979年 | 109篇 |
1978年 | 76篇 |
1977年 | 53篇 |
1976年 | 45篇 |
1975年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
《中国现代医生》2020,58(29):24-27+封三
目的 探讨肝癌组织中LncRNA TINCR 表达水平对术后长期生存的影响。方法 回顾性分析2013 年4 月~2016 年2 月间在本院接受手术治疗的157 例肝细胞肝癌患者的临床资料。RT-PCR 法检测肝癌标本内LncRNA TINCR 表达水平,采用ROC 曲线和Kaplan-Meier 法分析LncRNA TINCR 表达水平对肝癌术后长期生存的影响。结果 肝癌组织LncRNA TINCR 表达水平对术后长期生存预测的曲线下面积(AUC)为0.812,特异度为73.77%,灵敏度为79.17%,最佳判读值为1.89(P<0.0001)。根据ROC 曲线分析结果,将肝癌组织LncRNA TINCR 相对表达水平大于1.89 的93 例(59.24%)患者纳入高表达组,而肝癌组织LncRNA TINCR 相对表达水平小于或等于1.89的64 例(40.76%)患者纳入低表达组。Kaplan-Meier 法生存分析发现高表达组术后3 年内有76 例患者死亡,3 年总生存率为18.28%(17/93);低表达组术后3 年内有20 例患者死亡,3 年总生存率为68.75%(44/64),低表达组3 年总生存率明显优于高表达组(P<0.0001,两组间死亡风险比为3.7534,95%可信区间为2.5158~5.6000)。结论 肝癌组织LncRNA TINCR 表达水平与肝癌术后长期生存显著相关,LncRNA TINCR 表达水平升高则预示着预后不佳。 相似文献
23.
BackgroundTumor mutation burden (TMB) as a prognostic marker for immunotherapy has shown prognostic value in many cancers. However, there is no systematic investigation on TMB in papillary thyroid carcinoma (PTC).MethodsBased on the somatic mutation data of 487 PTC patients from The Cancer Genome Atlas (TCGA), TMB was calculated, and we classified the samples into high-TMB (H-TMB) and low-TMB (L-TMB) groups. Bioinformatics methods were used to explore the characteristics and potential mechanism of TMB in PTC.ResultsHigh TMB predicts shorter progression-free survival (PFS) (P < 0.001). TMB was positively correlated with age, stage, tumor size, metastasis, the male sex and tall cell PTC. Compared to the L-TMB group, the H-TMB group presented with lower immune cell infiltration, a higher proportion of tumor-promoting immune cells (M0 macrophages, activated dendritic cells and monocytes) and a lower proportion of antitumor immune cells (M1 macrophages, CD8+ T cells and B cells). Additionally, the characteristics displayed by different TMB groups were not driven by critical driver mutations such as BRAF and RAS.ConclusionsPTC patients with high TMB have a worse prognosis. By stratifying PTC patients according to their TMB, advanced PTC patients who are candidates for immunotherapy could be selected. 相似文献
24.
目的探讨接受选择性淋巴结照射(ENI)的食管鳞癌患者预后和失败模式。方法回顾性分析2005年1月至2012年12月河北医科大学第四医院收治的179例符合入组条件的食管鳞癌患者,分析肿瘤局部相关因素预测患者预后的价值,分析影响患者近期疗效、预后的影响因素,并对影响患者总生存率(OS)、无进展生存率(PFS)和复发的指标分别进行单因素和多因素分析。结果全组患者1、3、5年OS和PFS分别为77.1%、40.1%、26.0%和62.6%、30.6%、20.3%。多因素分析结果显示声音嘶哑、cN分期、cTNM分期、GTV-横径(GTV-D)和GTV-体积/长度(GTV-V/L)为影响患者OS的独立性影响因素(P<0.05);声音嘶哑、cTNM分期和近期疗效为影响患者PFS的独立性影响因素(P<0.05)。全组有75例(41.9%)患者出现复发,61例(34.1%)远处转移,其中19例(10.6%)为合并复发和远处转移。75例复发患者中64例(85.3%)患者为单纯食管复发,4例(5.3%)为单纯淋巴结复发,另7例(9.3%)患者为食管合并淋巴结复发。治疗后达完全缓解(CR)的63例患者中有18例患者出现复发,其中仅有2例患者出现淋巴结复发;logistic多因素分析结果显示患者周边组织/器官受侵、GTV-D和近期疗效为影响患者复发的独立性影响因素(P<0.05)。结论食管鳞癌患者接受ENI确实可行,其失败主要模式仍为食管复发;治疗前声音嘶哑、GTV-D和GTV-V/L较大、临床分期较晚和近期疗效不佳为患者预后较差的指标;肿瘤周边组织受侵、GTV-D和近期疗效是影响患者失败的独立性因素。 相似文献
25.
26.
27.
目的:探讨MRI在浸润性小叶癌(ILC)术前诊断中的应用价值,并评估乳腺密度对其影响。方法:选取75例术前30天内行MRI检查的I-Ⅲ期ILC患者列入本项研究,根据腺体含量评估乳腺密度,在MRI下测量肿瘤大小,并对比其与病理大小的一致性。结果:75例入组患者中26例(34.7%)患者经MRI评估发现新的可疑病灶,20例(26.7%)患者改变了手术方式。高密度乳腺型患者额外病灶检出率明显高于低密度乳腺型患者(51.6% vs 22.7%,P=0.010)。MRI评估肿瘤大小在低密度乳腺型患者中容易被低估(36.4% vs 12.9%,P=0.024),在高密度乳腺型患者中容易被高估(6.8% vs 29.0%,P=0.010),但两组患者与病理大小一致性的比例无明显差异。结论:ILC患者术前乳腺MRI检查能够提高额外恶性肿瘤的检出率,而乳腺密度是影响MRI评估的重要因素。 相似文献
28.
29.
《Journal of the American College of Radiology》2020,17(10):1207-1219
PurposeLobular neoplasia (LN) detected on breast core needle biopsy is frequently managed with surgical excision because of concern for undersampled malignancy. The authors performed a systematic review and meta-analysis to estimate the risk for upgrade to malignancy in the setting of imaging-concordant classic LN diagnosed on core biopsy.MethodsPubMed and Embase were searched for original articles published from 1998 to 2020 that reported rates of upgrade to malignancy for classic LN, including atypical lobular hyperplasia (ALH) and classic lobular carcinoma in situ (LCIS). Two reviewers extracted study data and assessed the following quality criteria: exclusion of variant LCIS, exclusion of imaging-discordant lesions, and outcome reporting for ≥70% of lesions. For studies meeting all criteria, pooled risks for upgrade to any malignancy (invasive carcinoma or ductal carcinoma in situ) and invasive malignancy for all LN, ALH, and LCIS were estimated using random-effects models.ResultsFor 65 full-text articles included in the review, the risk for upgrade to any malignancy ranged from 0% to 45%. Among the 16 studies that met all quality criteria for the meta-analysis, pooled risks for upgrade to any malignancy were 3.1% (95% confidence interval [CI], 1.8%-5.2%) for all LN, 2.5% (95% CI, 1.6%-3.9%) for ALH, and 5.8% (95% CI, 2.9%-11.3%) for LCIS. Risks for upgrade to invasive malignancy were 1.3% (95% CI, 0.7%-2.4%) for all LN, 0.4% (95% CI, 0.0%-4.2%) for ALH, and 3.5% (95% CI, 2.0%-5.9%) for LCIS.ConclusionsThe risk for upgrade to malignancy for LN found on breast biopsy is low. Imaging surveillance can likely be offered as an alternative to surgical management for LN, particularly for ALH. 相似文献
30.
Hui-Ju Ch’ang 《World journal of hepatology》2015,7(16):2029-2040
The success of sorafenib in prolonging survival of patients with hepatocellular carcinoma (HCC) makes therapeutic inhibition of angiogenesis a component of treatment for HCC. To enhance therapeutic efficacy, overcome drug resistance and reduce toxicity, combination of antiangiogenic agents with chemotherapy, radiotherapy or other targeted agents were evaluated. Nevertheless, the use of antiangiogenic therapy remains suboptimal regarding dosage, schedule and duration of therapy. The issue is further complicated by combination antiangiogenesis to other cytotoxic or biologic agents. There is no way to determine which patients are most likely respond to a given form of antiangiogenic therapy. Activation of alternative pathways associated with disease progression in patients undergoing antiangiogenic therapy has also been recognized. There is increasing importance in identifying, validating and standardizing potential response biomarkers for antiangiogenesis therapy for HCC patients. In this review, biomarkers for antiangiogenesis therapy including systemic, circulating, tissue and imaging ones are summarized. The strength and deficit of circulating and imaging biomarkers were further demonstrated by a series of studies in HCC patients receiving radiotherapy with or without thalidomide. 相似文献